ClinicalThought
View More
What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?
With the first 6 months of the COVID-19 pandemic behind us, I share how my management of patients with CLL has evolved based on experience and key data emerging on COVID-19 risk in patients with CLL.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.